Immediate Impact
1 standout
Citing Papers
Bispecific antibody drug conjugates: Making 1+1>2
2024 Standout
Works of Shahid Ashfaque being referenced
Abstract GS2-02: GS2-02 Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated survival results of the randomized, phase 3 study DESTINY-Breast03
2023
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Shahid Ashfaque | 67 | 45 | 12 | 16 | 7 | 76 | |
| Qilong Zhang | 41 | 29 | 14 | 11 | 8 | 50 | |
| Virginia Wolstenholme | 31 | 33 | 6 | 9 | 6 | 53 | |
| Sandeep H. Mashru | 69 | 53 | 20 | 9 | 6 | 94 | |
| Lyn Chan | 34 | 49 | 7 | 51 | 6 | 83 | |
| Manuel Ruíz-Borrego | 59 | 39 | 30 | 6 | 9 | 72 | |
| Álvaro Montaño | 56 | 12 | 13 | 9 | 7 | 73 | |
| Kristen Curtis | 28 | 69 | 7 | 33 | 10 | 82 | |
| Tanja Neunhöffer | 85 | 74 | 16 | 4 | 8 | 97 | |
| Vichitra Behel | 44 | 49 | 31 | 12 | 7 | 79 | |
| Jagdish Shetty | 72 | 37 | 11 | 12 | 7 | 79 |
All Works
Loading papers...